Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 2, 2006, Pages 149-152

  Cauza, E ^a   Hanusch Enserer, U ^a   Frischmuth, K ^a   Fabian, B ^a   Dunky, A ^a   Kostner, K ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b University of Brisbane   (Australia)

Author keywords

ACR criteria; Cartilage oligomeric matrix protein; Infliximab; Psoriatic arthritis; Tumour necrosis factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; RETINOID;

ADULT; ARTHRITIS; ARTICLE; BLOOD LEVEL; CARTILAGE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOTHERAPY; JOINT STIFFNESS; MALE; PSORIATIC ARTHRITIS; PUVA; SHORT COURSE THERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED;

EID: 33645464181     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00715.x     Document Type: Article

References (15)

1. Gladmann DD 1995 Psoriatic arthritis. Bailliere's clinical rheumatology 9 2 319 329
2. Gladman DD Shuckett R Russell ML Thorne JC Schachter RK 1987 Psoriatic arthritis analysis of 220 patients QJM 62 127 141
3. Elliott MJ Maini RN Feldmann M et al. 1993 Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factorà Arthritis and Rheumatism 36 1681 1690
4. Feldmann M Brennan FM Maini RN 1996 Role of cytokines in rheumatoid arthritis Annual Review of Immunology 14 397 440
5. Ritchlin C Haas-Smith SA Hicks D Cappuccio J Osterland CK Looney RJ 1998 Patterns of cytokine production in psoriatic synovium Journal of Rheumatology 25 1544 1552
6. Partsch G Wagner E Leeb BF Broll H Dunky A Smolen JS 1998 T cell derived cytokines in psoriatic arthritis synovial fluids Annals of the Rheumatic Diseases 57 691 693
7. Maini R St Clair EW Breedveld F et al. 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) vs. placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group Lancet 354 1932 1939
8. Mease P 2002 Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept Clinical and Experimental Rheumatology 20 Suppl. 28 S116 S121
9. Cauza E Spak M Cauza K Hanusch-Enserer U Dunky A Wagner E 2002 Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab Rheumatology International 22 227 232
10. Gladman D Farewell VT Nadeau C 1995 Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model Journal of Rheumatology 22 675 679
11. Christophers E Sterry W 1993 Psoriasis In: Fitzpatric TB Eisen AZ Wolff K Freedberg IM Austen KF eds Dermatology in general medicine New York McGraw-Hill 489 515
12. Saxne T Heinegard D 1992 Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood British Journal of Rheumatology 31 583 591
13. Marti C Neidhart M Gerber T Hauser N Michel BA Hauselmann HJ 1999 Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis Zeitschrift fur Rheumatologie 58 79 87
14. den Broeder AA Joosten LA Saxne T et al. 2002 Long term anti-tumor necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Annals of the Rheumatic Diseases 61 311 318
15. Saxne T Glennas A Kvien TK Melby K Heinegard D 1993 Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis Arthritis and Rheumatism 36 20 25